DASH
Repository logo
Communities & Collections
Browse DASH
DASH Stories
Statistics
  1. Home
  2. Harvard Division of Continuing Education
  3. DCE Theses and Dissertations
  4. Identifying Vulnerabilities and Novel Drug Candidates in Platinum-Resistant Ovarian Cancer.

Identifying Vulnerabilities and Novel Drug Candidates in Platinum-Resistant Ovarian Cancer.

Open/View files
Victor_Chiara_Thesis_May2024.pdf (1.17 MB)
Date
May 9, 2024
Author(s)
Victor, Chiara Alden
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Victor, Chiara Alden. 2024. Identifying Vulnerabilities and Novel Drug Candidates in Platinum-Resistant Ovarian Cancer.. Master's thesis, Harvard University Division of Continuing Education.
Abstract
Ovarian cancer is the fifth leading cause of female, cancer-related death in the United States and the deadliest form of gynecological cancer (Cancer Facts & Figures 2022, 2022). Epithelial ovarian cancer (EOC) accounts for 90% of all diagnosed ovarian cancers, 70% of which are High Grade Serous Ovarian Cancer (HGSOC), with a five- year survival rate less than 25% (Cai et al., 2014; Ediriweera et al., 2019; Iyengar et al., 2018; Lisio et al., 2019; Siwak et al., 2010). Platinum-taxane combination therapy has been the standard of care since its introduction in the 1990s yet, over 70% of HGSOC patients relapse due to platinum resistance (PR) (Kim et al., 2012; Kristedja et al., 2010; Moghbeli, 2021). There is a critical need for alternative therapeutic options for PR HGSOC. Here, we aimed to generate models of PR from HGSOC cell lines intrinsically sensitive to cisplatin and screen them against a panel of 225 small molecule inhibitors. The panel consists of FDA-approved drugs currently being used clinically, drugs in Phase II or III clinical trials, as well as novel-preclinical small molecule kinase inhibitors and tool compounds to identify single agents and/or pathways of interest in combating PR. Aligning with previous research, selective EGFR and PI3K inhibitors elicited significant responses in the PR model compared to the parental cell line. Lastly, the MEK inhibitor, cobimetinib, displayed advantageous responses in the PR model and highlight the MEK pathway to be further investigated in the context of PR HGSOC.
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service
URI
https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37378525
Subjects

Cisplatin

Ovarian Cancer

Platinum Resistance

Bioengineering

Nanotechnology

Collection
DCE Theses and Dissertations
Metrics
Repository logo
  • CONTACT US
  • OSRDS
  • ABOUT DASH
  • DEPOSITING TO DASH
  • TERMS OF USE
  • REQUEST A WAIVER
  • TAKE DOWN POLICY
  • NAME CHANGE POLICY
  • HARVARD OA POLICIES
  • DASH SUBMITTER AGREEMENT
  • Accessibility
  • Privacy
Creative Commons License BY
Creative Commons Attribution 4.0 International License

Except where otherwise noted, this work is subject to a Creative Commons Attribution 4.0 International License,
which allows anyone to share and adapt our material as long as proper attribution is given.
For details and exceptions, see the Harvard Library Copyright Policy
©2024 Presidents and Fellows of Harvard College.